The Weekly Litigation News Digest is now live. Subscribe now
Enantiomers Of Tetrahydro-N,N-Dimethyl-2,2-Diphenyl-3-Furanmethanamine (Anavex2-73) And Use Thereof In The Treatment Of Alzheimer'S Disease And Other Disorders Modulated By The Sigma 1 Receptor - EP3324956
The patent EP3324956 was granted to Anavex Life Sciences on Nov 20, 2024. The application was originally filed on Jul 19, 2016 under application number EP16827322A. The patent is currently recorded with a legal status of "Granted And Under Opposition".
EP3324956
- Application Number
- EP16827322A
- Filing Date
- Jul 19, 2016
- Status
- Granted And Under Opposition
- Oct 18, 2024
- Publication Date
- Nov 20, 2024
- External Links
- Slate, Register, Google Patents
Patent Summary
Patent Family
Patent Oppositions
Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.
Patent Citations (10) New
Patent citations refer to prior patents cited during different phases such as opposition or international search.
Dossier Documents
The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.
Date
Description
Get instant alerts for new documents